Pay in 4 interest-free payments of $5.89 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
In inflammatory bowel disease models including ulcerative colitis and cysteamine-induced colitis, BPC-157 reduces inflammatory markers (IL-6, TNF-, IL-1), improves mucosal architecture, and accelerates healing of damaged intestinal tissue
After 12 weeks, participants showed 42% improvement in skin firmness and 38% reduction in fine lines compared to placebo
This is not news: Sage Canaday has been going on about Cams usage for months now, and Hanes pretty much said yeah, so? @sagecanaday haha I have no idea if I could pass a drug test
BPC-157 remains investigational rather than proven therapy, so safety and effectiveness require stronger human clinical evidence before routine medical use
